Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 25Lymphoma 11Prostatic Neoplasms 9Lymphoma, Non-Hodgkin 9Lymphoma, T-Cell, Peripheral 8Lymphoma, Follicular 7Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Multiple Myeloma 5Neoplasms, Plasma Cell 4Lymphoma, Mantle-Cell 4Hodgkin Disease 3Burkitt Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Myasthenia Gravis 2Lymphoma, Large-Cell, Immunoblastic 2Immunoblastic Lymphadenopathy 2Subcutaneous panniculitis-like T-cell lymphoma 1Spinal Cord Neoplasms 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Plasmablastic Lymphoma 1Pituitary Neoplasms 1Neoplasms, Experimental 1Neoplasms 1Neoplasm Metastasis 1Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel 1Neoadjuvant Therapy 1Myelodysplastic Syndromes 1Lymphoma, T-Cell 1

Interventions

pembrolizumab 1pamiparib 1abiraterone 1Prednisone 1Folfox protocol 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoadjuvant Therapy × Prednisone × Clear all
NCT05376722 2023-01-05

A Study of Pamiparib Combined With Abiraterone Acetate in Neoadjuvant Treatment of Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
30 enrolled

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡